Skip to main content

Table 6 Comparison between fibroscan results in the studied patients

From: Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

  At the start of treatment 1 month of treatment At the end of treatment P-value
Fibroscan F0–F1 113 56.5% 113 56.5% 111 55.5% P1 = 1.0 NS
P2 = 0.973 NS
P3 = 0.973 NS
F1–F2 55 27.5% 55 27.5% 57 28.5%
F3–F4 32 16.5% 32 16.5% 32 16.5%
  1. X2: chi-square test
  2. S: p-value < 0.05 is considered significant
  3. HS: p-value < 0.001 is considered highly significant
  4. P1: refers to the statistical difference between the start of DAA and 1 month after DAA
  5. P2: refers to the statistical difference between the start of DAA and the end of DAA
  6. P3: refers to the statistical difference between 1 month after DAA and the end of DAA